Capricor Therapeutics (FRA:4LN2) Marketable Securities : €31.01 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Capricor Therapeutics's Marketable Securities for the quarter that ended in Mar. 2024 was €31.01 Mil.

Capricor Therapeutics's annual Marketable Securities increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€30.04 Mil) but then declined from Dec. 2022 (€30.04 Mil) to Dec. 2023 (€22.74 Mil).

Capricor Therapeutics Marketable Securities Historical Data

The historical data trend for Capricor Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Marketable Securities Chart

Capricor Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

5.39

30.04

22.74

Capricor Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															32.29	25.80	18.31	22.74	31.01

Capricor Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Capricor Therapeutics (FRA:4LN2) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Capricor Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics (FRA:4LN2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

CAPR:USA

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics (FRA:4LN2) Headlines

No Headlines